1) In summary, the results showed that ACT without a lymphodepleting regimen and with low doses of subcutaneous IL-2 was safe in heavily pre-treated patients with advanced melanoma 2) A higher percentage of CD4+ CD25+ CD127lowFoxp3+ T cells in the infused TIL population was associated with significantly shorter OS 3) Combining ACT with checkpoint inhibitors could potentiate the TIL effect, countering local immunodeficiency. Here, IL2 is linked to melanoma.